NCT03824483: An ongoing trial by Memorial Sloan Kettering Cancer Center
This trial is ongoing. It must report results 1 year, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03824483 |
|---|---|
| Title | Phase 2 Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) and Mantle Cell Lymphoma (MCL) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 22, 2019 |
| Completion date | Feb. 28, 2026 |
| Required reporting date | Feb. 28, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |